Medical Marijuana for ALS (Lou Gehrig's Disease) in Florida
A progressive neurodegenerative disease affecting motor neurons controlling movement.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord, leading to the loss of voluntary muscle control. Patients experience progressive weakness, muscle atrophy, clumsiness, slurred speech, difficulty swallowing and breathing, and uncontrollable emotional outbursts. The disease only worsens with time — symptoms that begin as mild twitching can progress to complete loss of mobility and respiratory failure.
ALS is almost universally fatal, with a median survival of 2–5 years from symptom onset. Approximately 5,000 Americans are diagnosed with ALS each year, and about 30,000 are living with the disease at any given time. The only FDA-approved medications — riluzole and edaravone — provide modest benefits at best. Riluzole extends life by only a few months and cannot regenerate damaged neurons, while edaravone may slow functional decline in a subset of patients. Treatment therefore focuses on a multidisciplinary approach including physical therapy, speech therapy, breathing support, nutritional assistance, and rigorous symptom management.
Florida explicitly lists ALS as a qualifying condition under Statute 381.986, recognizing the urgent need for comprehensive symptom relief in this devastating disease. ALS patients may also qualify under the terminal illness provision, which provides access to higher-potency products and different dosing allowances.
How Medical Cannabis May Help
Medical cannabis addresses multiple ALS symptom clusters simultaneously, making it a particularly valuable palliative tool. Carter and Rosen (American Journal of Hospice and Palliative Medicine, 2001) published a seminal review describing cannabis properties directly applicable to ALS management: analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. The same review noted preclinical evidence of neuroprotective effects that may prolong neuronal cell survival. A survey of ALS patients (Amtmann et al., American Journal of Hospice and Palliative Medicine, 2004) found that cannabis was reported moderately to highly effective for reducing appetite loss, depression, pain, spasticity, and drooling — all major quality-of-life concerns for ALS patients. In preclinical mouse models (G93A-SOD1), cannabinoid treatment prolonged neuronal cell survival, delayed disease onset, and slowed progression, suggesting neuroprotective mechanisms beyond simple symptom relief. The mechanism involves CB1 receptor activation that reduces excitatory glutamate neurotransmission — glutamate excitotoxicity is a key ALS disease mechanism and the same target as riluzole. Cannabinoids also provide potent antioxidant properties, protecting motor neurons from oxidative stress, while CB2 receptor activation on activated microglia reduces neuroinflammation surrounding degenerating motor neurons. For patients with swallowing difficulties — a common ALS complication — oral tinctures, edibles, oils, topical creams, and vaporized forms provide accessible delivery methods that don't require smoking. Dr. Stratt provides compassionate, expedited evaluations for ALS patients.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and neurology records confirming ALS diagnosis, current medication list, and documentation of symptoms being treated.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for ALS (Lou Gehrig's Disease)
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.